research Dihydrotestosterone and the Concept of 5α–Reductase Inhibition in Human Benign Prostatic Hyperplasia
Blocking the enzyme that turns testosterone into DHT can safely and effectively treat enlarged prostate.
Search
for
Sort by
Research
330-360 / 1000+ results
research A rapid method for obtaining finasteride, a 5α-reductase inhibitor, from commercial tablets
Quickly get finasteride from tablets using easy methods.
research Enhanced effect of fibroblast growth factor-2-containing dalteparin/protamine nanoparticles on hair growth
FGF-2&D/P nanoparticles can help treat hair loss.
research [A patient with advanced recurrent breast cancer who firmly resisted hair loss and was then treated by combination therapy with high-dose toremifene and capecitabine].
The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.
research [Study of gonadal hormone drugs in blocking filovirus entry of cells in vitro].
Some gonadal hormone drugs can block filovirus entry into cells.
research Endothelial NMMHC IIA dissociation from PAR1 activates the CREB3/ARF4 signaling in thrombin-mediated intracerebral hemorrhage
Targeting NMMHC IIA may help treat blood-brain barrier damage.
research 203 Rebalance of the scalp microbiota by a multifunctional ingredient
Dutasteride improved hair density and thickness in men not helped by finasteride, with minimal side effects.
research Postmarketing Surveillance of New Antiepileptic Drugs: The Tribulations of Trials
Monitoring new epilepsy drugs after they're sold is crucial to find rare and long-term side effects that initial tests might miss.
research OP-044 Midterm Results Following Percutaneous Rotational Thrombectomy for Acute Occlusions of Arteriovenous Access Grafts
The treatment successfully reopened blood flow in most patients and extended the use of their dialysis access with low risk.
research No Increased Cardiovascular Hazard with Oral 5-Alpha-Reductase Inhibitors in Treatment of Androgenetic Alopecia: A TriNetX Retrospective Cohort Study
Oral 5-alpha-reductase inhibitors for hair loss don't increase heart risk.
research Identification of Metabolites for the Novel 5α‐Reductase Inhibitor Epristeride In Vitro and Its Potential Impact on Doping Testing
Epristeride's metabolism involves key metabolites and proteins, affecting its use in doping tests.
research Sodium valproate and thrombocytopenia.
Sodium valproate can cause low platelet count.
research [Visual field defect in a patient given sodium valporate then carbamazepine: possible effect of aminotransferase inhibition].
Anti-epileptic drugs may cause visual and hair side effects due to enzyme inhibition, especially in genetically predisposed individuals.
research Evaluating 5 alpha reductase inhibitors for the treatment of male androgenic alopecia
Finasteride and dutasteride are effective in treating male hair loss but can cause sexual side effects and birth defects.
research Effect of Testosterone Supplementation With and Without a Dual 5α-Reductase Inhibitor on Fat-Free Mass in Men With Suppressed Testosterone Production
Testosterone's muscle-building effects do not require its conversion to DHT.
research Botulinum Toxin A Versus Dutasteride Mesotherapy Versus Platelet-Rich Plasma in the Treatment of Androgenetic Alopecia
research Finasteride Quantification in Human Plasma by High-Performance Liquid Chromatography Coupled to Electrospray Ionization Tandem Mass Spectrometry. Application to a Comparative Pharmacokinetics Study
New method measures finasteride in plasma, finds two formulations bioequivalent.
research Estranys matins de febrer: Pauline Fondevila
Trienones are more effective at inhibiting the enzyme linked to hair loss than dienones.
research RE: EFFECT OF THE DUAL 5α-REDUCTASE INHIBITOR DUTASTERIDE ON MARKERS OF TUMOR REGRESSION IN PROSTATE CANCER
Dutasteride may help shrink prostate cancer tumors.
research Baricitinib Provides Sustained, Long-Term Efficacy With Consistent Safety for Up to 5 Years of Treatment in Adults With Severe Alopecia Areata: Final Results From BRAVE-AA1 and BRAVE-AA2
Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.
research Trapa bispinosa Roxb. Pericarp Extract Exerts 5α-Reductase Inhibitory Activity in Castrated Benign Prostatic Hyperplasia Model Mice
Trapa bispinosa Roxb. extract may help reduce prostate size and cell growth in BPH.
research Analytical methods of dutasteride: An overview
Dutasteride is more effective than finasteride for hair loss treatment.
research Eczema-like, erythematous, infiltrated plaques: A common side effect of subcutaneous heparin therapy
Red, swollen skin patches are a common allergic reaction to heparin injections, and testing with different heparin types can help find a suitable treatment.
research Baricitinib: Exploring the Safety Profile for the Treatment of Alopecia Areata
Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.
research MP44-04 TRENDS IN 5-ALPHA REDUCTASE INHIBITOR USE BEFORE AND AFTER THE FOOD AND DRUG ADMINISTRATION SAFETY WARNING
Prescriptions for 5-alpha reductase inhibitors dropped significantly after the FDA's safety warning, especially for men with benign prostatic hyperplasia.
research Efficacy and safety of proxalutamide (GT0918) in severe or critically ill patients with COVID-19: study protocol for a prospective, open-label, single-arm, single-center exploratory trial
The trial will test if proxalutamide is safe and effective in reducing death in severe COVID-19 patients.
research EFFECT OF A COMBINATION OF DUTASTERIDE AND PARENTERAL TESTOSTERONE UNDECANOATE ON TESTOSTERONE DEFICIENCY SYMPTOMS AND PROSTATE IN PATIENTS WITH TESTOSTERONE DEFICIENCY AND BENIGN PROSTATIC HYPERPLASIA
The combination treatment reduced prostate size and improved testosterone deficiency symptoms but was less effective for sexual function.
research Post-marketing safety profile of cladribine in multiple sclerosis: a disproportionality analysis based on the FDA adverse event reporting system
Cladribine has known risks and potential new safety concerns, requiring careful monitoring.
research Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment
Baricitinib is generally safe for long-term use in treating severe alopecia areata.